Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACLOVATE vs NOXIVENT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Aclovate (alclometasone dipropionate) is a synthetic corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. Its mechanism involves binding to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reducing arachidonic acid release, and decreasing prostaglandin and leukotriene synthesis.
Noxivent is a synthetic analog of epinephrine that acts as a non-selective alpha and beta adrenergic receptor agonist. It binds to alpha-1 receptors causing vasoconstriction, alpha-2 receptors reducing insulin secretion, beta-1 receptors increasing heart rate and contractility, and beta-2 receptors causing bronchodilation and vasodilation. Its primary effect in septic shock is increasing mean arterial pressure via vasoconstriction.
Relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses (e.g., atopic dermatitis, contact dermatitis, eczema, psoriasis) - FDA approved,Off-label: Treatment of mild to moderate plaque psoriasis, seborrheic dermatitis, and lichen planus
Increase blood pressure in adults with septic shock who remain hypotensive despite adequate fluid resuscitation and treatment with vasopressors (e.g., norepinephrine) and inotropes (e.g., dobutamine) to maintain mean arterial pressure ≥65 mm Hg
Apply a thin film to affected skin areas twice daily. Not for ophthalmic, oral, or intravaginal use.
700 mg orally twice daily with food.
Terminal elimination half-life: approximately 6-8 hours after topical application; systemic absorption is minimal under normal use.
Terminal elimination half-life 4-6 hours; prolonged in renal impairment (up to 12 hours) requiring dose adjustment.
Aclovate is metabolized in the skin and liver via ester hydrolysis to inactive metabolites. Systemic metabolism primarily involves cytochrome P450 enzymes (CYP3A4) for any absorbed fraction, but extensive first-pass metabolism limits systemic exposure.
Primarily metabolized by monoamine oxidase (MAO) and catechol-O-methyltransferase (COMT) in the liver and other tissues. Also undergoes oxidation and conjugation.
Renal (primarily as metabolites, <5% unchanged), biliary/fecal (minor).
Primarily renal (70-80% unchanged), with 10-15% biliary/fecal. Minor metabolism via ester hydrolysis.
Approximately 90%, primarily to albumin and corticosteroid-binding globulin (CBG).
85-90% bound to albumin; reduced binding in hypoalbuminemia.
Not well-characterized in topical use; after systemic absorption, Vd is approximately 1-2 L/kg, indicating distribution into tissues.
0.8-1.2 L/kg; suggests extensive tissue distribution (e.g., lung, liver).
Topical: approximately 1-3% systemic absorption on intact skin; increased up to 15% on occluded or damaged skin.
Oral: 50-60% (first-pass metabolism); Sublingual: 70-80%; No data for other routes.
No dose adjustment required. Topical use with minimal systemic absorption.
GFR 30-59 m L/min: 350 mg twice daily; GFR <30 m L/min or on dialysis: 350 mg once daily.
No dose adjustment required. Topical use with minimal systemic absorption.
Child-Pugh A: no adjustment; Child-Pugh B: 350 mg twice daily; Child-Pugh C: not recommended.
Use smallest amount effective for shortest duration. Avoid prolonged use, occlusive dressings, or application to large surface areas. Safety in children <1 year not established.
Not approved for pediatric use.
Use with caution due to increased risk of skin atrophy and systemic absorption. Limit frequency and duration; avoid occlusive dressings.
No specific dose adjustment; monitor renal function and use lowest effective dose.
No FDA black box warning.
None.
Topical corticosteroids can cause hypothalamic-pituitary-adrenal (HPA) axis suppression, especially with prolonged use, large surface area, occlusion, or in pediatric patients.,Reversible HPA axis suppression may occur after discontinuation.,Systemic effects including Cushing's syndrome, hyperglycemia, and glucosuria have been reported.,Local adverse reactions: burning, itching, irritation, dryness, folliculitis, hypopigmentation, allergic contact dermatitis, maceration, secondary infection, skin atrophy, striae, and miliaria.,Use caution in patients with impaired skin integrity or areas of skin atrophy.,Pediatric patients may be more susceptible to systemic toxicity due to higher skin surface-to-body-weight ratio.
May cause severe hypertension, cardiac arrhythmias (especially with pre-existing conditions), tissue ischemia due to vasoconstriction, and exacerbation of heart failure. Use with caution in patients with hyperthyroidism, diabetes (as it increases blood glucose), and history of coronary artery disease.
Hypersensitivity to alclometasone dipropionate or any component of the formulation.,Untreated bacterial, fungal, or viral skin infections (e.g., herpes simplex, varicella, tuberculosis of the skin).
Hypersensitivity to noxivent or any component; uncontrolled hypertension; tachyarrhythmias; ventricular fibrillation; use with non-selective MAO inhibitors (risk of hypertensive crisis).
No known food interactions with topical Aclovate.
No specific food interactions reported. Grapefruit juice may increase formoterol levels (avoid if possible). Take with or without food.
Topical corticosteroids like ACLOVATE (alclometasone dipropionate) are generally considered low risk in pregnancy, but systemic absorption can occur. Class C: Fetal risk cannot be ruled out. Avoid extensive use or prolonged treatment, especially in first trimester. Second and third trimester: Use only if clearly needed, minimal area and duration.
NOXIVENT is a combination of a long-acting beta-agonist (LABA) and an inhaled corticosteroid (ICS). Inhaled beta-agonists have low systemic bioavailability and are generally considered low risk in pregnancy. Studies with inhaled corticosteroids (budesonide, fluticasone) show no increased risk of major malformations. First-trimester exposure data for LABAs are limited but do not indicate a significant teratogenic risk. However, high-dose systemic corticosteroids are associated with cleft palate. Inhaled doses minimize systemic exposure. Overall, NOXIVENT is considered safe for use in pregnancy when asthma control is necessary.
Safety unknown; likely minimal systemic absorption due to low potency. M/P ratio not established. Avoid application to breasts or large areas; use caution.
No data on NOXIVENT specific M/P ratio. Both components (beta-agonist and corticosteroid) are excreted in human milk in small amounts, but are unlikely to affect the infant due to low oral bioavailability. Inhaled doses result in minimal systemic concentrations. The American Academy of Pediatrics considers inhaled beta-agonists and corticosteroids compatible with breastfeeding. Use with caution, especially with high doses.
No standard dose adjustment required; however, limit potency, frequency, and duration to lowest effective due to altered skin permeability. No pharmacokinetic changes necessitate dose change.
No dose adjustment required for NOXIVENT based on pharmacokinetic changes in pregnancy. Asthma management guidelines recommend using standard doses to maintain control. However, pregnancy may alter asthma severity; dose titration is based on symptom control rather than pharmacokinetic adjustment. Consider step-down if asthma improves, step-up if worsens. Monitor for systemic effects of high doses (e.g., growth restriction from ICS).
Topical corticosteroids like Aclovate are classified as low-potency (Group VI). They are suitable for thin skin areas (e.g., face, flexures) and for children. Avoid prolonged use without interruption to minimize systemic absorption, especially in pediatric patients due to higher skin surface area-to-body weight ratio.
NOXIVENT (formoterol + glycopyrrolate) is a fixed-dose LABA/LAMA combination for COPD. Avoid use in asthma due to increased risk of asthma-related death. Monitor for paradoxical bronchospasm; discontinue immediately if occurs. Assess renal function before initiating glycopyrrolate (primarily renally excreted). Not for acute bronchospasm relief.
Apply a thin layer to affected skin only, not to normal surrounding skin.,Do not cover with bandages or dressings unless directed by your doctor.,Use for the prescribed duration; do not use longer than 2 weeks at a time.,Avoid contact with eyes, mouth, and open wounds.,Report any signs of skin thinning, redness, or irritation to your healthcare provider.
Use exactly as prescribed; do not exceed recommended dose or frequency.,This medication is for maintenance treatment of COPD, not for acute symptoms. Always have a rescue inhaler (e.g., albuterol) available.,Rinse mouth with water after each dose to prevent thrush (oral candidiasis).,Report worsening breathing, chest tightness, or signs of allergic reaction (rash, hives, swelling) immediately.,Do not stop using NOXIVENT without consulting your doctor, even if you feel better.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACLOVATE vs NOXIVENT, answered by our medical review team.
ACLOVATE is a Topical Corticosteroid that works by Aclovate (alclometasone dipropionate) is a synthetic corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. Its mechanism involves binding to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reducing arachidonic acid release, and decreasing prostaglandin and leukotriene synthesis.. NOXIVENT is a Beta-2 Agonist Bronchodilator that works by Noxivent is a synthetic analog of epinephrine that acts as a non-selective alpha and beta adrenergic receptor agonist. It binds to alpha-1 receptors causing vasoconstriction, alpha-2 receptors reducing insulin secretion, beta-1 receptors increasing heart rate and contractility, and beta-2 receptors causing bronchodilation and vasodilation. Its primary effect in septic shock is increasing mean arterial pressure via vasoconstriction.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACLOVATE and NOXIVENT depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACLOVATE is: Apply a thin film to affected skin areas twice daily. Not for ophthalmic, oral, or intravaginal use.. The standard adult dose of NOXIVENT is: 700 mg orally twice daily with food.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACLOVATE and NOXIVENT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACLOVATE is classified as Category C. Topical corticosteroids like ACLOVATE (alclometasone dipropionate) are generally considered low risk in pregnancy, but systemic absorption can occur. Class C: Fetal risk cannot be . NOXIVENT is classified as Category C. NOXIVENT is a combination of a long-acting beta-agonist (LABA) and an inhaled corticosteroid (ICS). Inhaled beta-agonists have low systemic bioavailability and are generally consid. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.